How should we approach management of childhood onset chronic anterior uveitis refractory to adalimumab?
Expert Rev Clin Immunol. 2023 Nov 21:1-10. doi: 10.1080/1744666X.2023.2284845. Online ahead of print.ABSTRACTINTRODUCTION: The management of refractory juvenile idiopathic associated uveitis (JIAU) or childhood-onset chronic anterior uveitis (CAU) is a challenge. There is no clear consensus or evidence base for to suggest the most appropriate therapy after primary or secondary failure of biweekly adalimumab. In this scenario, most clinicians advocate switching to another anti-tumor necrosis factor alpha inhibitor; however, there are a variety of other disease modifying agents to choose from albeit with a differing levels o...
Source: Expert Review of Clinical Immunology - November 22, 2023 Category: Allergy & Immunology Authors: Ivan Foeldvari Harry Petrushkin Source Type: research
Low relapse rate in patients with giant cell arteritis in a multi-centre retrospective Turkish Registry
CONCLUSIONS: In this first multi-centre series of GCA from Turkey, we observed that only one-fifth of patients had relapses during a mean follow-up of 26 months, with 76.4% given a GC-sparing IS agent at diagnosis. At the end of follow-up, GC-related side effects developed in one-fourth of patients. Our results suggest that patients with GCA had a low relapse rate in real-life experience of a multi-centre retrospective Turkish registry, however with a significant presence of GC-associated side effects during follow-up.PMID:37976117 | DOI:10.55563/clinexprheumatol/zr7s0g (Source: Clinical and Experimental Rheumatology)
Source: Clinical and Experimental Rheumatology - November 17, 2023 Category: Rheumatology Authors: Fatma Alibaz- Öner Bahar Kelesoglu Mehmet Ali Balci G özde Kübra Yardimci Berkan Arma ğan Levent Kili ç Özlem Karakaş Abdulsamet Erden Sule Yasar Bilge Riza Can Karda ş Hamit K üçük Orhan Zengin Murat Tasci Sinem Burcu Kocaer Sule Yavuz Atalay Source Type: research
